Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain

Brain Research

Volumn 802, Issue 1-2, 1998, Pages 111-118

  Rassoulpour, Arash ^a   Wu, Hui Qiu ^a   Poeggeler, Burkhard ^a   Schwarcz, Robert ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Drug abuse; Excitatory amino acid; Kynurenine; Monoamine; Ontogeny

Indexed keywords

DEXAMPHETAMINE; EXCITATORY AMINO ACID RECEPTOR; KYNURENIC ACID; KYNURENINE;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CELL LEVEL; DOSE TIME EFFECT RELATION; DRUG ABUSE; HIPPOCAMPUS; LIVER LEVEL; MALE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; TISSUE LEVEL;

ANIMALS; ANIMALS, NEWBORN; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; EXCITATORY AMINO ACID ANTAGONISTS; EXTRACELLULAR SPACE; KYNURENIC ACID; KYNURENINE; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0344110533     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00577-0     Document Type: Article

References (58)

1. P. Andiné, A. Lehmann, K. Ellrén, E. Wennberg, I. Kjellmer, T. Nielsen, H. Hagberg, The excitatory amino acid antagonist kynurenic acid administered after hypoxic ischemia in neonatal rats offers neuroprotection, Neurosci. Lett. 90 (1988) 208-212.
2. K. Asgar, E. De Souza, Pharmacology and toxicology of amphetamine and related designer drugs, in: K. Asgar, E. De Souza (Eds.), NIDA Research Monographs 94, 1989, pp. 1-25.
3. M.F. Beal, W.R. Matson, E. Storey, P. Milbury, E.A. Ryan, T. Ogawa, E.D. Bird, Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex, J. Neurol. Sci. 108 (1992) 80-87.
4. Y. Ben-Ari, R. Khazipov, X. Leinekugel, O. Gaillard, J.-L. Gaiarsa, GABAA, NMDA and AMPA receptors: a developmentally regulated 'ménage à trois', Trends Neurosci. 20 (1997) 523-529.
5. T.V.P. Bliss, G.L. Collingridge, A synaptic model of memory: long-term potentiation in the hippocampus, Nature 361 (1993) 31-39.
6. G. Ceresoli, P. Guidetti, R. Schwarcz, Kynurenic acid production in the rat striatum: acute and chronic effects of quinolinate lesions, Soc. Neurosci. Abstr. 22 (1996) 608.12.
7. A. Chiarugi, R. Carpenedo, M.T. Molina, L. Mattoli, R. Pellicciari, F. Moroni, Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase, J. Neurochem. 65 (1995) 1176-1183.
8. D.W. Choi, Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage, Trends Neurosci. 11 (1988) 465-469.
9. A.C. Foster, A. Vezzani, E.D. French, R. Schwarcz, Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid, Neurosci. Lett. 48 (1984) 273-278.
10. R.W. Fuller, S.K. Hembrick-Luecke, P.L. Ornstein, Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist, Neuropharmacology 31 (1992) 1027-1032.
11. R. Gill, G.N. Woodruff, The neuroprotective actions of kynurenic acid and MK-801 in gerbils are synergistic and not related to hypothermia, Eur. J. Pharmacol. 176 (1990) 143-149.
12. J.B.P. Gramsbergen, P.S. Hodgkins, A. Rassoulpour, W.A. Turski, P. Guidetti, R. Schwarcz, Brain-specific modulation of kynurenic acid synthesis in the rat, J. Neurochem. 69 (1997) 290-298.
13. 3H-kynurenine in the rat brain in vivo: evidence for the existence of a functional kynurenine pathway, J. Neurochem. 65 (1995) 2621-2632.
14. P. Guidetti, E. Okuno, R. Schwarcz, Characterization of rat brain kynurenine aminotransferases I and II, J. Neurosci. Res. 50 (1997) 457-465.
15. 3H]MK801 binding, Eur. J. Pharmacol. 281 (1995) R11-R13.
16. P. Hodgkins, R. Schwarcz, Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate, Eur. J. Neurosci. 10 (1998) 1986-1994.
17. D.A. Hutchins, The effect of pargyline and desmethylimipramine on monoamine concentrations and amphetamine-induced glycogenolysis in the mouse brain, Br. J. Pharmacol. 65 (1979) 489-494.
18. K. Hyrc, S.D. Handran, S.M. Rothman, M.P. Goldberg, Ionized intracellular calcium concentration predicts excitotoxic neuronal death: observations with low-affinity fluorescent calcium indicators, J. Neurosci. 17 (1997) 6669-6677.
19. C. Ikonomidou, M.T. Price, J.L. Mosinger, G. Frierdich, J. Labruyere, K.S. Salles, J.W. Olney, Hypobaric - ischemic conditions produce glutamate-like cytopathology in infant rat brain, J. Neurosci. 9 (1989) 1693-1700.
20. D. Jauch, E.M. Urbańska, P. Guidetti, E.D. Bird, J.-P.G. Vonsattel, W.O. Whetsell Jr., R. Schwarcz, Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases, J. Neurol. Sci. 130 (1995) 39-47.
21. A.E. Kelley, J.M. Delfs, Excitatory amino acid receptors mediate the orofacial stereotypy elicited by dopaminergic stimulation of the ventrolateral striatum, Neuroscience 60 (1994) 85-95.
22. M. Kessler, T. Terramani, G. Lynch, M. Baudry, A glycine site associated with N-methyl-D-aspartic acid receptors: characteristics and identification of a new class of antagonists, J. Neurochem. 52 (1989) 1319-1328.
23. H. Komura, P. Rakic, Modulation of neuronal migration by NMDA receptors, Science 260 (1993) 95-97.
24. C. Konradi, J.-C. Levesque, S.E. Hyman, Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium, J. Neurosci. 16 (1996) 4231-4239.
25. P.D. Leeson, L.L. Iversen, The glycine site on the NMDA receptor-activity relationships and therapeutic potential, J. Med. Chem. 37 (1994) 4053-4067.
26. O.H. Lowry, N.J. Rosebrough, N.J. Farr, R.J. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem. 193 (1951) 265-273.
27. J.W. McDonald, F.S. Silverstein, M.V. Johnston, Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system, Brain Res. 459 (1988) 200-203.
28. A.F. Miranda, R.J. Boegman, R.J. Beninger, K. Jhamandas, Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid, Neuroscience 78 (1997) 967-975.
29. K.E. Moore, The actions of amphetamine on neurotransmitters: a brief review, Biol. Psychiatry 12 (1977) 451-462.
30. F. Moroni, R. Carpenedo, A. Chiarugi, Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system, Adv. Exp. Med. Biol. 398 (1996) 203-210.
31. F. Moroni, P. Russi, V. Carlà, G. Lombardi, Kynurenic acid is present in the rat brain and its content increases during development and aging process, Neurosci. Lett. 94 (1988) 145-150.
32. K. Nozaki, M.F. Beal, Neuroprotective effects of L-kynurenine on hypoxia - ischemia and NMDA lesions in neonatal rats, J. Cereb. Blood Flow Metab. 12 (1992) 400-407.
33. C.G. Parsons, W. Danysz, G. Quack, S. Hartmann, B. Lorenz, C. Wollenburg, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, B. Chizh, P.M. Headley, Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization, J. Pharmacol. Exp. Ther. 283 (1997) 1264-1275.
34. R. Pellicciari, B. Natalini, G. Costantino, M.R. Mahmoud, L. Mattoli, B.M. Sadeghpour, F. Moroni, A. Chiarugi, R. Carpenedo, Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)-alanine, a potent inhibitor of kynurenine-3-hydroxylase, J. Med. Chem. 37 (1994) 647-655.
35. W.E. Pelham Jr., K.E. Greenslade, M. Vodde-Hamilton, D.A. Murphy, J.J. Greenstein, E.M. Gnagy, K.J. Guthrie, M.D. Hoover, R.E. Dahl, Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextro-amphetamine, and pemoline, Pediatrics 2 (1990) 226-237.
36. A. Pittaluga, R. Rattarini, M. Raiteri, Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors, Eur. J. Pharmacol. 271 (1995) 203-210.
37. A. Pittaluga, D. Vaccari, M. Raiteri, The kynurenate test, a biochemical assay for putative cognition enhancers, J. Pharmacol. Exp. Ther. 283 (1997) 82-90.
38. B. Poeggeler, A. Rassoulpour, P. Guidetti, H.-Q. Wu, R. Schwarcz, Dopaminergic control of kynurenate levels and NMDA toxicity in the developing rat striatum, Dev. Neurosci. (1998), in press.
39. S. Rabacchi, Y. Bailly, N. Delhaye-Bouchaud, J. Mariani, Involvement of the N-methyl-D-aspartate (NMDA) receptor in synapse elimination during cerebellar development, Science 256 (1992) 1823-1825.
40. A. Rassoulpour, H.-Q. Wu, B. Poeggeler, R. Schwarcz, D-Amphetamine and reserpine modulate kynurenic acid levels in the rat brain in vivo, Soc. Neurosci. Abstr. 22 (1996) 39.15.
41. K. Sakimura, T. Kutsuwada, I. Ito, T. Manabe, C. Takayama, E. Kushlya, T. Yagl, S. Aizawa, Y. Inoue, H. Sugiyama, M. Mishina, Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon1 subunit, Nature 373 (1995) 151-155.
42. A.J. Scheetz, M. Constantine-Paton, Modulation of NMDA receptor function: implications for vertebrate neural development, FASEB J. 8 (1994) 745-752.
43. R. Schwarcz, F. Du, W. Schmidt, W.A. Turski, J.B.P. Gramsbergen, E. Okuno, R.C. Roberts, Kynurenic acid: a potential pathogen in brain disorders, Ann. New York Acad. Sci. 648 (1992) 140-153.
44. R. Schwarcz, A.C. Foster, E.D. French, W.O. Whetsell Jr., C. Köhler, Excitotoxic models for neurodegenerative diseases, Life Sci. 35 (1984) 19-32.
45. R. Schwarcz, P. Guidetti, R.C. Roberts, Quinolinic acid and kynurenic acid: glia-derived modulators of excitotoxic brain injury, in: M. Aschner, H.K. Kimelberg (Eds.), The Role of Glia in Neurotoxicity, CRC Press, Boca Raton, FL, 1996, pp. 245-262.
46. C. Speciale, H.-Q. Wu, M. Cini, M. Marconi, M. Varasi, R. Schwarcz, (R,S)-3,4-dichloro-benzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats, Eur. J. Pharmacol. 315 (1996) 263-267.
47. C. Speciale, H.-Q. Wu, J.B.P. Gramsbergen, W.A. Turski, U. Ungerstedt, R. Schwarcz, Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid, Neurosci. Lett. 116 (1990) 198-203.
48. D.N. Stephens, A glutamatergic hypothesis of drug dependence: extrapolations from benzodiazepine receptor ligands, Behav. Pharmacol. 6 (1995) 425-446.
49. T.W. Stone, Neuropharmacology of quinolinic and kynurenic acids, Pharmacol. Rev. 45 (1993) 309-379.
50. A.M. Thomson, Glycine is a coagonist at the NMDA receptor/channel complex, Prog. Neurobiol. 35 (1990) 53-74.
51. W.A. Turski, J.B.P. Gramsbergen, H. Traitler, R. Schwarcz, Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine in the rat, J. Neurochem. 52 (1989) 1629-1636.
52. W.A. Turski, M. Nakamura, W.P. Todd, B.K. Carpenter, W.O. Whetsell Jr., R. Schwarcz, Identification and quantification of kynurenic acid in human brain tissue, Brain Res. 454 (1988) 164-169.
53. W.A. Turski, R. Schwarcz, On the disposition of intrahippocampally injected kynurenic acid in the rat, Exp. Brain Res. 71 (1988) 563-567.
54. E.M. Urbańska, T. Kocki, T. Saran, Z. Kleinrok, W.A. Turski, Impairment of brain kynurenic acid production by glutamate metabotropic receptor agonists, NeuroReport 8 (1997) 3501-3505.
55. K.S. Wilcox, R.M. Fitzsimonds, B. Johnson, M.A. Dichter, Glycine regulation of synaptic NMDA receptors in hippocampal neurons, J. Neurophysiol. 76 (1996) 3415-3424.
56. H.-Q. Wu, H. Baran, U. Ungerstedt, R. Schwarcz, Kynurenic acid in the quinolinate-lesioned rat hippocampus: studies in vitro and in vivo, Eur. J. Neurosci. 4 (1992) 1264-1270.
57. H.-Q. Wu, P. Guidetti, G. Ceresoli, C. Post, M. Varasi, C. Speciale, R. Schwarcz, Prevention of excitotoxicity after manipulation of the kynurenine pathway in the rat, Soc. Neurosci. Abstr. 23 (1997) 903.10.
58. H.-Q. Wu, R. Schwarcz, Seizure activity causes elevation of endoge-nous extracellular kynurenic acid in the rat brain, Brain Res. Bull. 39 (1996) 155-162.